PLATFORM Study of Precision Medicine for Rare Tumors

NCT04423185 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

770

Enrollment

OTHER

Sponsor class

Conditions

Rare Tumor

Interventions

DRUG: Almonertinib 110 MG
DRUG: Dacomitinib 45 MG
DRUG: Alectinib 150 MG
DRUG: Crizotinib 250 MG
DRUG: Pyrotinib 160/80 MG
DRUG: Imatinib 400 MG
DRUG: Niraparib 200/300 MG
DRUG: Palbociclib 125mg
DRUG: Vemurafenib 240 MG
DRUG: Sintilimab 100MG
DRUG: Atezolizumab 1680 MG

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences